Structure Therapeutics Inc.
GPCR
$19.61
$0.241.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.00M | 51.52M | 49.41M | 46.79M | 42.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 219.66M | 182.52M | 158.23M | 142.16M | 122.47M |
| Operating Income | -219.66M | -182.52M | -158.23M | -142.16M | -122.47M |
| Income Before Tax | -178.49M | -142.94M | -122.22M | -110.69M | -100.26M |
| Income Tax Expenses | 465.00K | 379.00K | 310.00K | -138.00K | 175.00K |
| Earnings from Continuing Operations | -178.95 | -143.32 | -122.53 | -110.55 | -100.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.95M | -143.32M | -122.53M | -110.55M | -100.44M |
| EBIT | -219.66M | -182.52M | -158.23M | -142.16M | -122.47M |
| EBITDA | -218.55M | -181.48M | -157.23M | -141.34M | -121.84M |
| EPS Basic | -9.36 | -7.72 | -6.95 | -6.63 | -6.71 |
| Normalized Basic EPS | -1.81 | -1.47 | -1.31 | -1.33 | -1.35 |
| EPS Diluted | -9.36 | -7.72 | -6.95 | -6.63 | -6.71 |
| Normalized Diluted EPS | -1.81 | -1.47 | -1.31 | -1.33 | -1.35 |
| Average Basic Shares Outstanding | 229.41M | 221.28M | 210.50M | 199.51M | 180.62M |
| Average Diluted Shares Outstanding | 76.47M | 73.76M | 70.17M | 66.50M | 60.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |